By Samantha Reynolds
Globus Medical (NASDAQ
: GMED) recently received a number of ratings updates from brokerages and research firms:
- 5/7/2015 – Globus Medical was upgraded by analysts at Zacks from a “hold” rating to a “buy” rating. They now have a $28.00 price target on the stock. Zacks’ analyst wrote, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
- 5/6/2015 – Globus Medical had its price target raised by analysts at Brean Capital from $30.00 to $33.00. They now have a “buy” rating on the stock. They wrote, “GMED expects the momentum to continue, but is only increasing revenue guidance to $514 million from $510 million and EPS to $1.02 from $1.01—which looks even more conservative than before. As such, we are raising our estimates for the year to $523.4 million from $513.1 million and our EPS to $1.05 from $1.01 —this does not assume an R&D tax credit, which would add another $0.03-$0.04.”
- 5/6/2015 – Globus Medical had its “outperform” rating reaffirmed by analysts at Oppenheimer. They now have a $28.00 price target on the stock.
